Global Precision Psychiatry Market - GLOBAL:2021

Market Report Coverage :
Start Year : 2021 - Forecast Year : 2026 - Start Value : $779.0 Million in 2021 - Forecast Value : $1,727.4 Million by 2026 - CAGR % : 0.17%
Description :
Market Report Coverage - Precision PsychiatryMarket Segmentation• Product Type– Products and Services• Sample Type – Blood-Based and Non-Blood-Based (Saliva, CSF, Urine, and others)• Biomarker Type – Genetic Biomarker and Protein Biomarker• Technology – Sequencing (NGS and Sanger Sequencing), Polymerase Chain Reaction (RT-PCR and dPCR), Microarray, Immunoassay, Liquid Chromatography-Mass Spectrometry (LC-MS) and Other Technologies• Application – Alzheimer’s Disease, Parkinson’s Disease, Autism, Depression, Bipolar Disease, and Other Applications• End User – Academic and Research Institutions, Hospitals and Diagnostic Laboratories, and Other End UsersRegional Segmentation• North America – U.S., and Canada• Europe – Germany, U.K., France, Italy, Spain, Netherlands, and Rest-of-Europe• Asia-Pacific – China, Japan, India, Australia, South Korea, and Rest-of-Asia-Pacific• Latin America – Brazil, Mexico, and Rest-of-Latin America• Rest-of-the-WorldGrowth Drivers• Decreasing Cost of Sequencing• Increasing Adoption of Inorganic Growth Strategies• Global Increase in Mental Health BurdenMarket Challenges• Lack of Established Regulatory Policies for Precision Diagnostics in the Field of Precision Psychiatry• Lack of Awareness for Precision Psychiatry DiagnosticsMarket Opportunities• Increased Use of Precision Diagnostics for Drug Development by Pharmaceutical and Companion Diagnostics Companies• Massive Scope for Adoption of NGS-Based Genetic Tests in Emerging MarketsKey Companies ProfiledIllumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, ARUP Laboratories, Invitae Corporation, OPKO Health, Inc., Laboratory Corporation of America Holdings, Centogene N.V., Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Konica Minolta, Inc., Fulgent Genetics, PreventionGeneticsKey Questions Answered in this Report:• How is precision psychiatry revolutionizing the field of mental health diagnostics?• What are the major market drivers, challenges, and opportunities in the global precision psychiatry market?• What are the underlying structures resulting in the emerging trends within the global precision psychiatry market?• How is the COVID-19 pandemic impacting the global precision psychiatry landscape?• What are the key development strategies that are being implemented by the major players in order to sustain in the competitive market?• What are the key regulatory implications in developed and developing regions pertaining to precision psychiatry?• What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region? • How is each segment of the market expected to grow during the forecast period from 2021 to 2026, and what is the anticipated revenue to be generated by each of the segments? Following are the segments: o Product Type (Products and Services) o Sample (Blood-Based and Non-Blood-Based) o Biomarker (Genetic Biomarkers and Protein) o Technology (Sequencing, PCR, Microarray, Immunoassay, LC/MS, and Others) o Application (Parkinson’s Disease, Autism, Alzheimer’s Disease, Depression, Schizophrenia, Bipolar Disorder, and Others) o End User (Hospitals and Diagnostic Laboratories, Academic and Research Institutions, and Others) o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)• What are the growth opportunities for the companies in the region of their operation?• Who are the leading players with significant offerings in the global precision psychiatry market? • Which companies are anticipated to be highly disruptive in the future, and why?• What are the current unmet needs that are being faced in the global precision psychiatry market?Market OverviewOur healthcare experts have found the precision psychiatry market to be one of the most rapidly evolving and dynamic markets, and the global market for precision psychiatry is predicted to grow at a CAGR of 17.26% over the forecast period of 2021-2026. The market is driven by certain factors, which include decreasing cost of sequencing, increasing adoption of inorganic growth strategies, and global increase in mental health burden, that are fuelling the growth of the global precision psychiatry market.The market is favored by the developments in the field of molecular diagnostics, which are used for the diagnosis and assessment of psychiatric disorders. Currently, the precision psychiatry industry is witnessing an upsurge due to the decreasing cost of sequencing, increasing adoption of inorganic growth strategies, and global increase in mental health burden. Additionally, the high adoption of advanced molecular diagnostic technologies by the researchers to conduct genomic and proteomic analysis related to the onset and manifestation of psychiatric disorders are some of the critical factors that are expected to bolster the market growth.Furthermore, biotechnology companies are focusing on the development of robust precision psychiatry solutions for a wide range of applications to support clinicians in conducting an in-depth molecular analysis.Within the research report, the market is segmented on the basis of product type, biomarker, sample, technology, application, end user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.Competitive LandscapeThe exponential rise in the number of cases associated with psychiatric disorders has created a buzz among the biotechnology companies to further invest in the development of molecular diagnostics for the assessment of mental disorders, further aiding clinicians to offer precision medicine. Due to the presence of a diverse product portfolio and intense market penetration, Quest Diagnostics Incorporated has been a pioneer in the precision psychiatry ecosystem.On the basis of region, North America holds the largest share of the precision psychiatry market due to high infusion of funding from the government organizations for conducting research on psychiatric disorders, growing prevalence of mental disorders, growing awareness about precision medicine, and increasing awareness about early detection, among others. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR of 20.54% during the forecast period, 2021-2026.
Countries Covered :
North America U.S. CanadaEurope Germany Italy France Spain U.K. Netherlands Rest-of-EuropeAsia-Pacific China India South Korea Australia Japan Rest-of-Asia-PacificLatin America Brazil Mexico Rest-of-Latin AmericaRest-of-World
Keywords :
Precision Psychiatry, Precision Psychiatry Market, Precision Psychiatry Industry, Precision Psychiatry Report, Precision Psychiatry Market Forecasts, Precision Psychiatry Market Trends, Precision Psychiatry Market Products, Precision Psychiatry Market Applications, Precision Psychiatry Market Companies, Precision Psychiatry Market Analysis, Precision Psychiatry Industry Analysis, What is Precision Psychiatry, Precision Psychiatry Definition, FDA Regulation Precision Psychiatry Market, CMS Regulation Precision Psychiatry Market, Parkinson’s Disease Precision Psychiatry Market, Autism Precision Psychiatry Market, Alzheimer's Disease Precision Psychiatry Market, Depression Precision Psychiatry Market, Schizophrenia Precision Psychiatry Market, Bipolar Disorder Precision Psychiatry Market, Protein Biomarkers Precision Psychiatry Market, Saliva Precision Psychiatry Market, Urine Precision Psychiatry Market, Cerebral Spinal Fluid Precision Psychiatry Market, Next-Generation Sequencing Precision Psychiatry Market, Sanger Sequencing Precision Psychiatry Market, Polymerase Chain Reaction Precision Psychiatry Market, Real-Time Polymerase Chain Reaction Precision Psychiatry Market, Digital Polymerase Chain Reaction Precision Psychiatry Market, Microarray Precision Psychiatry Market, Immunoassay Precision Psychiatry Market, Liquid Chromatography-Mass Spectrometry Precision Psychiatry Market, Hospitals and Diagnostic Laboratories Precision Psychiatry Market, Academic and Research Institutions Precision Psychiatry Market, North America Precision Psychiatry Market, Europe Precision Psychiatry Market, Asia-Pacific Precision Psychiatry Market, Latin America Precision Psychiatry Market
Press Release :
The global precision psychiatry market is projected to reach $1.72 billion by 2026, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 17.26% during the period 2021-2026.The comprehensive study of the global precision psychiatry market by BIS Research extensively covers the following:• Market numbers on micro-segments that are influencing the market• More than 150 products present in the market• Over 25 brands were evaluated• Market share analysis for more than 20 product categories• End-user preference data for over 50 end users• Detailed global and regional market share analysis including the scrutiny of more than 15 countries• Study of data of more than 30 companiesBesides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of 200+ products.BIS Research study indicates that the decreasing cost of sequencing, increasing adoption of inorganic growth strategies in the market, and global increase in mental health burden are fueling the growth of the global precision psychiatry market.The market intelligence by BIS Research additionally throws a spotlight on the opportunities existing in the market, such as increased use of precision diagnostics for drug development by pharmaceutical and companion diagnostics companies and massive scope for adoption of NGS-based genetic tests in emerging markets.To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include product type, biomarker, sample, technology, applications, end users, and regions. The biomarker, technology, application, and region segments have been further sub-segmented to offer an in-depth analysis of the global precision psychiatry market.The product and ecosystem analysis of the global market include data analysis on the satisfaction level of different pricing analysis of preferred precision psychiatry products and services. Pertaining to the market segmentation, the product segment is segmented into products and services. The biomarker segment has been segregated into genetic biomarkers and protein biomarkers. The sample type segment is categorized into blood-based and non-blood samples. The technology segment has been broadly segmented into sequencing, polymerase chain reaction (PCR), microarray, immunoassay, liquid chromatography-mass spectrometry (LC-MS), and other technologies. The application segment has been segmented into Alzheimer’s disease, Parkinson’s disease, autism, depression, schizophrenia, bipolar disorder, and other applications. Furthermore, the end user segment has been further segmented into hospitals and diagnostic laboratories, academic and research institutions, and other end users.Key insights are drawn from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The key players profiled in the report include Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, ARUP Laboratories, Invitae Corporation, OPKO Health, Inc., Laboratory Corporation of America Holdings, CENTOGENE N.V., Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Konica Minolta, Inc., Fulgent Genetics, and PreventionGenetics.The study also offers strategic recommendations that can help organizations in tracking various products and trends that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.Who should buy this report?• Manufacturers and service providers who are involved in the development and commercialization of precision psychiatry solutions• Emerging companies in the field of precision psychiatry to assess the market situationHow can market intelligence on Precision Psychiatry add value to an organization’s decision-making process?• Aid in product and service development • Help in targeting a segment for launching new products and services • Offer go-to market access strategies • Support in diversifying the product portfolio basis risk and progression of underlying technologies • Help in analyzing specifications• Aid in understanding the end-user landscape• Gain holistic views pertaining to the regions and understand the market potential of the countries.• Support in analyzing the competitive landscape to gain an understanding of the business strategies incorporated by the companiesInsightful Questions Covered to Enable Companies to take Strategic Decisions• How is precision psychiatry revolutionizing the field of mental health diagnostics?• What are the major market drivers, challenges, and opportunities in the global precision psychiatry market?• What are the underlying structures resulting in the emerging trends within the global precision psychiatry market?• How is the COVID-19 pandemic impacting the global precision psychiatry landscape?• What are the key development strategies that are being implemented by the major players in order to sustain in the competitive market?• What are the key regulatory implications in developed and developing regions pertaining to precision psychiatry?• What are the potential entry barriers, which are expected to be faced by the companies willing to enter in a particular region? • How is each segment of the market expected to grow during the forecast period from 2021 to 2026 and what is the anticipated revenue to be generated by each of the segments? Following are the segments: o Product Type (Products and Services) o Sample (Blood-Based and Non-Blood-Based) o Biomarker (Genetic Biomarkers and Protein) o Technology (Sequencing, PCR, Microarray, Immunoassay, LC/MS, and Others) o Application (Parkinson’s Disease, Autism, Alzheimer’s Disease, Depression, Schizophrenia, Bipolar Disorder, and Others) o End User (Hospitals and Diagnostic Laboratories, Academic and Research Institutions, and Others) o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)• What are the growth opportunities for the companies in the region of their operation?• Who are the leading players with significant offerings in the global precision psychiatry market? • Which companies are anticipated to be highly disruptive in the future, and why?• What are the current unmet needs that are being faced in the global precision psychiatry market?
Companies Mentioned :
Illumina, Inc.F. Hoffmann-La Roche Ltd.Bio-Rad Laboratories, Inc.QIAGEN N.V.Quest Diagnostics IncorporatedARUP LaboratoriesInvitae CorporationOPKO Health, Inc.Laboratory Corporation of America HoldingsCENTOGENE N.V.Thermo Fisher Scientific Inc.Myriad Genetics, Inc.Konica Minolta, Inc.Fulgent GeneticsPreventionGenetics
Press Release :
The global precision psychiatry market is projected to reach $1.72 billion by 2026, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 17.26% during the period 2021-2026.The comprehensive study of the global precision psychiatry market by BIS Research extensively covers the following:• Market numbers on micro-segments that are influencing the market• More than 150 products present in the market• Over 25 brands were evaluated• Market share analysis for more than 20 product categories• End-user preference data for over 50 end users• Detailed global and regional market share analysis including the scrutiny of more than 15 countries• Study of data of more than 30 companiesBesides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of 200+ products.BIS Research study indicates that the decreasing cost of sequencing, increasing adoption of inorganic growth strategies in the market, and global increase in mental health burden are fueling the growth of the global precision psychiatry market.The market intelligence by BIS Research additionally throws a spotlight on the opportunities existing in the market, such as increased use of precision diagnostics for drug development by pharmaceutical and companion diagnostics companies and massive scope for adoption of NGS-based genetic tests in emerging markets.To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include product type, biomarker, sample, technology, applications, end users, and regions. The biomarker, technology, application, and region segments have been further sub-segmented to offer an in-depth analysis of the global precision psychiatry market.The product and ecosystem analysis of the global market include data analysis on the satisfaction level of different pricing analysis of preferred precision psychiatry products and services. Pertaining to the market segmentation, the product segment is segmented into products and services. The biomarker segment has been segregated into genetic biomarkers and protein biomarkers. The sample type segment is categorized into blood-based and non-blood samples. The technology segment has been broadly segmented into sequencing, polymerase chain reaction (PCR), microarray, immunoassay, liquid chromatography-mass spectrometry (LC-MS), and other technologies. The application segment has been segmented into Alzheimer’s disease, Parkinson’s disease, autism, depression, schizophrenia, bipolar disorder, and other applications. Furthermore, the end user segment has been further segmented into hospitals and diagnostic laboratories, academic and research institutions, and other end users.Key insights are drawn from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The key players profiled in the report include Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, ARUP Laboratories, Invitae Corporation, OPKO Health, Inc., Laboratory Corporation of America Holdings, CENTOGENE N.V., Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Konica Minolta, Inc., Fulgent Genetics, and PreventionGenetics.The study also offers strategic recommendations that can help organizations in tracking various products and trends that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.Who should buy this report?• Manufacturers and service providers who are involved in the development and commercialization of precision psychiatry solutions• Emerging companies in the field of precision psychiatry to assess the market situationHow can market intelligence on Precision Psychiatry add value to an organization’s decision-making process?• Aid in product and service development • Help in targeting a segment for launching new products and services • Offer go-to market access strategies • Support in diversifying the product portfolio basis risk and progression of underlying technologies • Help in analyzing specifications• Aid in understanding the end-user landscape• Gain holistic views pertaining to the regions and understand the market potential of the countries.• Support in analyzing the competitive landscape to gain an understanding of the business strategies incorporated by the companiesInsightful Questions Covered to Enable Companies to take Strategic Decisions• How is precision psychiatry revolutionizing the field of mental health diagnostics?• What are the major market drivers, challenges, and opportunities in the global precision psychiatry market?• What are the underlying structures resulting in the emerging trends within the global precision psychiatry market?• How is the COVID-19 pandemic impacting the global precision psychiatry landscape?• What are the key development strategies that are being implemented by the major players in order to sustain in the competitive market?• What are the key regulatory implications in developed and developing regions pertaining to precision psychiatry?• What are the potential entry barriers, which are expected to be faced by the companies willing to enter in a particular region? • How is each segment of the market expected to grow during the forecast period from 2021 to 2026 and what is the anticipated revenue to be generated by each of the segments? Following are the segments: o Product Type (Products and Services) o Sample (Blood-Based and Non-Blood-Based) o Biomarker (Genetic Biomarkers and Protein) o Technology (Sequencing, PCR, Microarray, Immunoassay, LC/MS, and Others) o Application (Parkinson’s Disease, Autism, Alzheimer’s Disease, Depression, Schizophrenia, Bipolar Disorder, and Others) o End User (Hospitals and Diagnostic Laboratories, Academic and Research Institutions, and Others) o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)• What are the growth opportunities for the companies in the region of their operation?• Who are the leading players with significant offerings in the global precision psychiatry market? • Which companies are anticipated to be highly disruptive in the future, and why?• What are the current unmet needs that are being faced in the global precision psychiatry market?
Headline :
Global Precision Psychiatry Market to Reach $1.72 Billion by 2026
Table of Contents :
Executive Summary 1 Product Definition1.1 Inclusion and Exclusion2 Market Scope2.1 Scope of the Study2.2 Key Questions Answered in the Report3 Research Methodology3.1 Global Precision Psychiatry Market: Research Methodology3.2 Data Sources3.2.1 Primary Data Sources3.2.2 Secondary Data Sources3.3 Market Estimation Model3.4 Criteria for Company Profiling4 Market Overview4.1 Market Definition4.2 Market Footprint and Growth Potential4.3 Future Potential4.4 COVID-19 Impact: Global Precision Psychiatry Market5 Market Dynamics5.1 Overview5.2 Market Drivers5.2.1 Decreasing Cost of Sequencing5.2.2 Increasing Adoption of Inorganic Growth Strategies in the Market5.2.3 Global Increase in Mental Health Burden5.3 Market Restraints5.3.1 Lack of Established Regulatory Policies for Precision Diagnostics in the Field of Precision Psychiatry5.3.2 Lack of Awareness for Precision Psychiatry Diagnostics5.4 Market Opportunities5.4.1 Increased Use of Precision Diagnostics for Drug Development by Pharmaceutical and Companion Diagnostics Companies5.4.2 Massive Scope for Adoption of NGS-based Genetic Tests in Emerging Markets6 Industry Insights6.1 Overview6.2 Legal Requirements and Framework in the U.S.6.2.1 FDA Regulation6.2.2 CMS Regulation6.3 Legal Requirements and Framework in Europe6.4 Legal Requirements and Framework in Asia-Pacific6.4.1 China6.4.2 Japan6.4.3 South Korea6.4.4 Australia7 Competitive Landscape7.1 Product Launches7.2 Product Approvals and Designations7.3 Synergistic Activities7.4 Acquisitions7.5 Funding7.6 Market Share Analysis, by Company, 2019–20207.7 Growth Share Analysis7.7.1 Growth Share Analysis (by Company)8 Global Precision Psychiatry Market (by Product Type)8.1 Overview8.2 Products8.3 Services9 Global Precision Psychiatry Market (by Biomarker Type)9.1 Overview9.2 Genetic Biomarkers9.2.1 Genetic Biomarkers (by Application)9.2.1.1 Parkinson’s Disease9.2.1.2 Autism9.2.1.3 Alzheimer's Disease9.2.1.4 Depression9.2.1.5 Schizophrenia9.2.1.6 Bipolar Disorder9.2.1.7 Other Applications9.3 Protein Biomarkers9.3.1 Protein Biomarkers (by Application)9.3.1.1 Parkinson’s Disease9.3.1.2 Autism9.3.1.3 Alzheimer's Disease9.3.1.4 Depression9.3.1.5 Schizophrenia9.3.1.6 Bipolar Disorder9.3.1.7 Other Applications10 Global Precision Psychiatry Market (by Sample)10.1 Overview10.2 Blood-Based10.3 Non-Blood-Based10.3.1 Saliva10.3.2 Urine10.3.3 Cerebral Spinal Fluid (CSF)10.3.4 Others11 Global Precision Psychiatry Market (by Technology)11.1 Overview11.2 Sequencing11.2.1 Next-Generation Sequencing (NGS)11.2.2 Sanger Sequencing11.3 Polymerase Chain Reaction (PCR)11.3.1 Real-Time Polymerase Chain Reaction (RT-PCR)11.3.2 Digital Polymerase Chain Reaction (dPCR)11.4 Microarray11.5 Immunoassay11.6 Liquid Chromatography-Mass Spectrometry (LC-MS)11.7 Other Technologies12 Global Precision Psychiatry Market (by Application)12.1 Overview12.2 Alzheimer’s Disease12.2.1 Global Precision Psychiatry Market for Alzheimer’s Disease (by Technology)12.3 Parkinson’s Disease12.3.1 Global Precision Psychiatry Market for Parkinson’s Disease (by Technology)12.4 Autism12.4.1 Global Precision Psychiatry Market for Autism (by Technology)12.5 Depression12.5.1 Global Precision Psychiatry Market for Depression (by Technology)12.6 Schizophrenia12.6.1 Global Precision Psychiatry Market for Schizophrenia (by Technology)12.7 Bipolar Disorder12.7.1 Global Precision Psychiatry Market for Bipolar Disorder (by Technology)12.8 Other Applications13 Global Precision Psychiatry Market (by End User)13.1 Overview13.2 Hospitals and Diagnostic Laboratories13.3 Academic and Research Institutions13.4 Other End Users14 Global Precision Psychiatry Market (by Region)14.1 Overview14.2 North America14.2.1 U.S.14.2.2 Canada14.3 Europe14.3.1 Germany14.3.2 UK.14.3.3 France14.3.4 Italy14.3.5 Spain14.3.6 Netherlands14.3.7 Rest-of-Europe14.4 Asia-Pacific14.4.1 China14.4.2 Japan14.4.3 South Korea14.4.4 Australia14.4.5 India14.4.6 Rest-of-Asia-Pacific14.5 Latin America14.5.1 Brazil14.5.2 Mexico14.5.3 Rest-of-Latin America14.6 Rest-of-the-World (RoW)15 Company Profiles15.1 Overview15.2 Illumina, Inc.15.2.1 Company Overview15.2.2 Role of Illumina, Inc. in the Global Precision Psychiatry Market15.2.3 Financials15.2.4 Key Insights About Financial Health of the Company15.2.5 SWOT Analysis15.3 F. Hoffmann-La Roche Ltd.15.3.1 Company Overview15.3.2 Role of F. Hoffmann-La Roche Ltd in the Global Precision Psychiatry Market15.3.3 Financials15.3.4 Key Insights About Financial Health of the Company15.3.5 SWOT Analysis15.4 Bio-Rad Laboratories, Inc.15.4.1 Company Overview15.4.2 Role of Bio-Rad Laboratories, Inc. in the Global Precision Psychiatry Market15.4.3 Financials15.4.4 Key Insights About Financial Health of the Company15.4.5 SWOT Analysis15.5 QIAGEN N.V.15.5.1 Company Overview15.5.2 Role of QIAGEN N.V. in the Global Precision Psychiatry Market15.5.3 Financials15.5.4 Key Insights about Financial Health of the Company15.5.5 SWOT Analysis15.6 Quest Diagnostics Incorporated15.6.1 Company Overview15.6.2 Role of Quest Diagnostics Incorporated in the Global Precision Psychiatry Market15.6.3 Financials15.6.4 SWOT Analysis15.7 ARUP Laboratories15.7.1 Company Overview15.7.2 Role of ARUP Laboratories in the Global Precision Psychiatry Market15.7.3 SWOT Analysis15.8 Invitae Corporation15.8.1 Company Overview15.8.2 Role of Invitae Corporation, Inc. in the Global Precision Psychiatry Market15.8.3 Financials15.8.4 Key Insights About Financial Health of the Company15.8.5 SWOT Analysis15.9 OPKO Health, Inc.15.9.1 Company Overview15.9.2 Role of OPKO Health, Inc. in the Global Precision Psychiatry Market15.9.3 Financials15.9.4 Key Insights About Financial Health of the Company15.9.5 SWOT Analysis15.1 Laboratory Corporation of America Holdings15.10.1 Company Overview15.10.2 Role of Laboratory Corporation of America Holdings in the Global Precision Psychiatry Market15.10.3 Financials15.10.4 SWOT Analysis15.11 CENTOGENE N.V.15.11.1 Company Overview15.11.2 Role of CENTOGENE N.V. in Precision Psychiatry Market15.11.3 Financials15.11.4 Key Insights About Financial Health of the Company15.11.5 SWOT Analysis15.12 Thermo Fisher Scientific Inc.15.12.1 Company Overview15.12.2 Role of Thermo Fisher Scientific Inc. in Global Precision Psychiatry Market15.12.3 Financials15.12.4 Key Insights About Financial Health of the Company15.12.5 SWOT Analysis15.13 Myriad Genetics, Inc.15.13.1 Company Overview15.13.2 Role of Myriad Genetics, Inc. in the Global Precision Psychiatry Market15.13.3 Financials15.13.4 Key Insights About Financial Health of the Company15.13.5 SWOT Analysis15.14 Konica Minolta, Inc.15.14.1 Company Overview15.14.2 Role of Konica Minolta, Inc. in the Global Precision Psychiatry Market15.14.3 Financials15.14.4 Key Insights About Financial Health of the Company15.14.5 SWOT Analysis15.15 Fulgent Genetics15.15.1 Company Overview15.15.2 Role of Fulgent Genetics in the Global Precision Psychiatry Market15.15.3 Financials15.15.4 Key Insights About Financial Health of the Company15.15.5 SWOT Analysis15.16 PreventionGenetics15.16.1 Company Overview15.16.2 Role of the PreventionGenetics in the Global Precision Psychiatry Market15.16.3 SWOT AnalysisList of Tables Table 8.1: Products Offered by Key PlayersTable 8.2: Services Offered by Key PlayersTable 12.1: Precision Psychiatry Products for Alzheimer’s DiseaseTable 12.2: Precision Psychiatry Services for Alzheimer’s DiseaseTable 12.3: Precision Psychiatry Products for Parkinson’s DiseaseTable 12.4: Precision Psychiatry Services for Parkinson’s DiseaseTable 12.5: Precision Psychiatry Products for AutismTable 12.6: Precision Psychiatry Services for AutismTable 12.7: Precision Psychiatry Products for DepressionTable 12.8: Precision Psychiatry Service for DepressionTable 12.9: Precision Psychiatry Products for SchizophreniaTable 12.10: Precision Psychiatry Services for SchizophreniaTable 12.11: Precision Psychiatry Products for Bipolar DisorderTable 12.12: Precision Psychiatry Service for Bipolar DisorderTable 12.13: Precision Psychiatry Products for Other ApplicationsTable 12.14: Precision Psychiatry Service for Other ApplicationsList of Figures Figure 1: Global Burden of Prominent Psychiatric Disorders (2014-2019)Figure 2: Impact Analysis of Market Drivers and Market Challenges on Global Precision Psychiatry MarketFigure 3: Global Precision Psychiatry Market (by Product Type), $Million, 2020 Vs. 2026Figure 4: Global Precision Psychiatry Market (by Biomarker), $Million, 2020 Vs. 2026Figure 5: Global Precision Psychiatry Market (by Sample), $Million, 2020 Vs. 2026Figure 6: Global Precision Psychiatry Market (by Technology), $Million, 2020 Vs. 2026Figure 7: Global Precision Psychiatry Market (by Application), $Million, 2020 Vs. 2026Figure 8: Global Precision Psychiatry Market (by End User), $Million, 2020 Vs. 2026Figure 9: Global Precision Psychiatry: Market SnapshotFigure 2.1: Global Precision Psychiatry Market: SegmentationFigure 3.1: Global Precision Psychiatry Market: MethodologyFigure 3.2: Primary Research MethodologyFigure 3.3: Bottom-Up Approach (Segment-Wise Analysis)Figure 3.4: Top-Down Approach (Segment-Wise Analysis)Figure 4.1: Global Precision Psychiatry Market, $Million, 2020-2026Figure 4.2: Global Precision Psychiatry Market: COVID-19 ImpactFigure 5.1: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)Figure 5.2: Synergistic Activities, FY2017-FY2020Figure 5.3: Global Burden of Prominent Psychiatric Disorders (2014-2019)Figure 6.1: FDA IVD Classification and Regulatory ProcessFigure 6.2: Key Changes in EU IVD Regulation 2017/746Figure 6.3: Europe’s IVD Regulatory Approval ProcessFigure 6.4: Medical Device Regulatory Approval Process in ChinaFigure 6.5: Medical Device Regulatory Approval Process in South KoreaFigure 6.6: Classification of IVD DevicesFigure 6.7: Medical Device (IVDs) Regulatory Approval Process in AustraliaFigure 7.1: Share of Key Developments and Strategies, January 2017–March 2021Figure 7.2: Share of Product Launched (by Company), January 2017–March 2021Figure 7.3: Share of Product Approvals and Designations (by Company), January 2017-March 2021Figure 7.4: Share of Synergistic Activities (by Company), January 2017-March 2021Figure 7.5: Share of Acquisitions (by Company), January 2017-March 2021Figure 7.6: Share of Funding (by Company), January 2017-March 2021Figure 7.7: Market Share Analysis for Global Precision Psychiatry Market, 2019 and 2020Figure 7.8: Growth Share Analysis for Global Precision Psychiatry Market (by Company), 2020Figure 8.1: Global Precision Psychiatry Market (by Product Type)Figure 8.2: Global Precision Psychiatry Market (by Product Type), 2020-2026Figure 8.3: Global Precision Psychiatry Market (Product), $Million, 2020-2026Figure 8.4: Global Precision Psychiatry Market (Services), $Million, 2020-2026Figure 9.1: Global Precision Psychiatry Market (by Biomarker Type), $Million, 2020-2026Figure 9.2: Global Precision Psychiatry Market (by Biomarker Type), 2020 and 2026Figure 9.3: Global Precision Psychiatry Market (Genetic Biomarkers), $Million, 2020-2026Figure 9.4: Global Precision Psychiatry Market for Genetic Biomarkers (Parkinson’s Disease), $Million, 2020-2026Figure 9.5: Global Precision Psychiatry Market for Genetic Biomarkers (Autism), $Million, 2020-2026Figure 9.6: Global Precision Psychiatry Market for Genetic Biomarkers (Alzheimer’s Disease), $Million, 2020-2026Figure 9.7: Global Precision Psychiatry Market for Genetic Biomarkers (Depression), $Million, 2020-2026Figure 9.8: Global Precision Psychiatry Market for Genetic Biomarkers (Schizophrenia), $Million, 2020-2026Figure 9.9: Global Precision Psychiatry Market for Genetic Biomarkers (Bipolar Disorder), $Million, 2020-2026Figure 9.10: Global Precision Psychiatry Market for Genetic Biomarkers (Other Applications), $Million, 2020-2026Figure 9.11: Global Precision Psychiatry Market (Protein Biomarkers), $Million, 2020-2026Figure 9.12: Global Precision Psychiatry Market for Protein Biomarkers (Parkinson’s Disease), $Million, 2020-2026Figure 9.13: Global Precision Psychiatry Market for Protein Biomarkers (Autism), $Million, 2020-2026Figure 9.14: Global Precision Psychiatry Market for Protein Biomarkers (Alzheimer’s Disease), $Million, 2020-2026Figure 9.15: Global Precision Psychiatry Market for Protein Biomarkers (Depression), $Million, 2020-2026Figure 9.16: Global Precision Psychiatry Market for Protein Biomarkers (Schizophrenia), $Million, 2020-2026Figure 9.17: Global Precision Psychiatry Market for Protein Biomarkers (Bipolar Disorder), $Million, 2020-2026Figure 9.18: Global Precision Psychiatry Market for Protein Biomarkers (Other Applications), $Million, 2020-2026Figure 10.1: Global Precision Psychiatry Market (by Sample)Figure 10.2: Global Precision Psychiatry Market (by Sample), 2020-2026Figure 10.3: Global Precision Psychiatry Market (Blood-Based), $Million, 2020-2026Figure 10.4: Global Precision Psychiatry Market (Non-Blood-Based), $Million, 2020-2026Figure 10.5: Global Precision Psychiatry Market (by Non-Blood-based Samples), $Million, 2020-2026Figure 10.6: Global Precision Psychiatry Market (Saliva), $Million, 2020-2026Figure 10.7: Global Precision Psychiatry Market (Urine), $Million, 2020-2026Figure 10.8: Global Precision Psychiatry Market (CSF), $Million, 2020-2026Figure 10.9: Global Precision Psychiatry Market (Other Samples), $Million, 2020-2026Figure 11.1: Global Precision Psychiatry Market (by Technology)Figure 11.2: Global Precision Psychiatry Market (by Technology), 2020-2026Figure 11.3: Global Precision Psychiatry Market (by Sequencing), $Million, 2020-2026Figure 11.4: Global Precision Medicine Market (by Sequencing), 2020 and 2026Figure 11.5: Global Precision Psychiatry Market (by NGS), $Million, 2020-2026Figure 11.6: Global Precision Psychiatry Market (by Sanger Sequencing), $Million, 2020-2026Figure 11.7: Global Precision Psychiatry Market (by PCR), $Million, 2020-2026Figure 11.8: Global Precision Psychiatry Market (by PCR), 2020 and 2026Figure 11.9: Global Precision Psychiatry Market (RT-PCR), $Million, 2020-2026Figure 11.10: Global Precision Psychiatry Market (dPCR), $Million, 2020-2026Figure 11.11: Global Precision Psychiatry Market (Microarray), $Million, 2020-2026Figure 11.12: Global Precision Psychiatry Market (Immunoassay), $Million, 2020-2026Figure 11.13: Global Precision Psychiatry Market (LC-MS), $Million, 2020-2026Figure 11.14: Global Precision Psychiatry Market (Others Technologies), $Million, 2020-2026Figure 12.1: Global Precision Psychiatry Market (by Application)Figure 12.2: Global Precision Psychiatry Market (by Application), $Million, 2020-2026Figure 12.3: Global Precision Psychiatry Market (Alzheimer’s Disease), $Million, 2020-2026Figure 12.4: Growth-Share Analysis for Global Precision Psychiatry Market for Alzheimer’s Disease (by Technology), 2020-2026Figure 12.5: Global Precision Psychiatry Market (Parkinson’s Disease), $Million, 2020-2026Figure 12.6: Growth-Share Analysis for Global Precision Psychiatry Market for Parkinson’s Disease (by Technology), 2020-2026Figure 12.7: Global Precision Psychiatry Market (Autism), $Million, 2020-2026Figure 12.8: Growth-Share Analysis for Global Precision Psychiatry Market for Autism (by Technology), 2020-2026Figure 12.9: Global Precision Psychiatry Market (Depression), $Million, 2020-2026Figure 12.10: Growth-Share Analysis for Global Precision Psychiatry Market for Depression (by Technology), 2020-2026Figure 12.11: Global Precision Psychiatry Market (Schizophrenia), $Million, 2020-2026Figure 12.12: Growth-Share Analysis for Global Precision Psychiatry Market for Schizophrenia (by Technology), 2020-2026Figure 12.13: Global Precision Psychiatry Market (Bipolar Disorder), $Million, 2020-2026Figure 12.14: Growth-Share Analysis for Global Precision Psychiatry Market for Bipolar Disorder (by Technology), 2020-2026Figure 12.15: Global Precision Psychiatry Market (Other Applications), $Million, 2020-2026Figure 13.1: Global Precision Psychiatry Market (by End User)Figure 13.2: Global Precision Psychiatry Market (by End User), $Million, 2020-2026Figure 13.3: Global Precision Psychiatry Market (Hospitals and Diagnostic Laboratories), $Million, 2020-2026Figure 13.4: Global Precision Psychiatry Market (Academic and Research Institutions), $Million, 2020-2026Figure 13.5: Global Precision Psychiatry Market (Other End Users), $Million, 2020-2026Figure 14.1: Global Precision Psychiatry Market (by Region), 2020 and 2026Figure 14.2: Global Precision Psychiatry Market (by Region), $Million, 2020-2026Figure 14.3: Global Precision Psychiatry Market (by Region), 2020-2026Figure 14.4: North America Precision Psychiatry Market, $Million, 2020-2026Figure 14.5: North America: Market DynamicsFigure 14.6: North America Precision Psychiatry Market (by Country), $Million, 2020-2026Figure 14.7: U.S. Precision Psychiatry Market, $Million, 2020-2026Figure 14.8: Canada Precision Psychiatry Market, $Million, 2020-2026Figure 14.9: Europe Precision Psychiatry Market, $Million, 2020-2026Figure 14.10: Europe: Market DynamicsFigure 14.11: Europe Precision Psychiatry Market (by Country), $Million, 2020-2026Figure 14.12: Germany Precision Psychiatry Market, $Million, 2020-2026Figure 14.13: U.K. Precision Psychiatry Market, $Million, 2020-2026Figure 14.14: France Precision Psychiatry Market, $Million, 2020-2026Figure 14.15: Italy Precision Psychiatry Market, $Million, 2020-2026Figure 14.16: Spain Precision Psychiatry Market, $Million, 2020-2026Figure 14.17: Netherlands Precision Psychiatry Market, $Million, 2020-2026Figure 14.18: Rest-of-Europe Market, $Million, 2020-2026Figure 14.19: Asia-Pacific Precision Psychiatry Market, $Million, 2020-2026Figure 14.20: APAC: Market DynamicsFigure 14.21: APAC Precision Psychiatry Market (by Country), $Million, 2020-2026Figure 14.22: China Precision Psychiatry Market, $Million, 2020-2026Figure 14.23: Japan Precision Psychiatry Market, $Million, 2020-2026Figure 14.24: South Korea Precision Psychiatry Market, $Million, 2020-2026Figure 14.25: Australia Precision Psychiatry Market, $Million, 2020-2026Figure 14.26: India Precision Psychiatry Market, $Million, 2020-2026Figure 14.27: RoAPAC Precision Psychiatry Market, $Million, 2020-2026Figure 14.28: Latin America Precision Psychiatry Market, $Million, 2020-2026Figure 14.29: Latin America: Market DynamicsFigure 14.30: Latin America Precision Psychiatry Market (by Country), $Million, 2020-2026Figure 14.31: Brazil Precision Psychiatry Market, $Million, 2020-2026Figure 14.32: Mexico Precision Psychiatry Market, $Million, 2020-2026Figure 14.33: Rest-of-Latin America Precision psychiatry Market, $Million, 2020-2026Figure 14.34: RoW Precision Psychiatry Market, $Million, 2021-2026Figure 15.1: Total Number of Companies ProfiledFigure 15.2: Illumina, Inc.: Product PortfolioFigure 15.3: Illumina, Inc.: Overall Financials, 2018-2020Figure 15.4: Illumina, Inc.: Revenue (by Segment), 2018-2020Figure 15.5: Illumina, Inc.: Revenue (by Region), 2018-2020Figure 15.6: Illumina, Inc.: R&D Expenditure, 2018-2020Figure 15.7: Illumina, Inc.: SWOT AnalysisFigure 15.8: F. Hoffmann-La Roche Ltd: PortfolioFigure 15.9: F. Hoffmann-La Roche Ltd: Overall Financials, 2018-2020Figure 15.10: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2018-2020Figure 15.11: F. Hoffmann-La Roche Ltd: Sales (by Region), 2018-2020Figure 15.12: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2020Figure 15.13: F. Hoffmann-La Roche: SWOT AnalysisFigure 15.14: Bio-Rad Laboratories, Inc.: PortfolioFigure 15.15: Bio-Rad Laboratories, Inc.: Overall Financials, 2018-2020Figure 15.16: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2018-2020Figure 15.17: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2018-2020Figure 15.18: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2018-2020Figure 15.19: Bio-Rad Laboratories, Inc.: SWOT AnalysisFigure 15.20: QIAGEN N.V.: PortfolioFigure 15.21: QIAGEN N.V.: Overall Financials, 2018-2020Figure 15.22: QIAGEN N.V.: Revenue (by Segment), 2018-2020Figure 15.23: QIAGEN N.V.: Revenue (by Region), 2018-2020Figure 15.24: QIAGEN N.V.: R&D Expenditure, 2018-2020Figure 15.25: QIAGEN N.V.: SWOT AnalysisFigure 15.26: Quest Diagnostics Incorporated: PortfolioFigure 15.27: Quest Diagnostics Incorporated: Overall Financials, 2018-2020Figure 15.28: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2018-2020Figure 15.29: Quest Diagnostics Incorporated: SWOT AnalysisFigure 15.30: ARUP Laboratories: PortfolioFigure 15.31: ARUP Laboratories: SWOT AnalysisFigure 15.32: Invitae Corporation: PortfolioFigure 15.33: Invitae Corporation: Overall Financials, 2018-2020Figure 15.34: Invitae Corporation: Revenue (by Segment), 2018-2020Figure 15.35: Invitae Corporation: Revenue (by Geography), 2018-2020Figure 15.36: Invitae Corporation: R&D Expenditure, 2018-2020Figure 15.37: Invitae Corporation: SWOT AnalysisFigure 15.38: OPKO Health, Inc.: PortfolioFigure 15.39: OPKO Health, Inc.: Overall Financials, 2018-2020Figure 15.40: OPKO Health, Inc.: Revenue (by Segment), 2018-2020Figure 15.41: OPKO Health, Inc.: Revenue (by Region), 2018-2020Figure 15.42: OPKO Health, Inc.: R&D Expenditure, 2018-2020Figure 15.43: OPKO Health, Inc.: SWOT AnalysisFigure 15.44: Laboratory Corporation of America Holdings: PortfolioFigure 15.45: Laboratory Corporation of America Holdings: Overall Financials, 2018-2020Figure 15.46: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020Figure 15.47: Laboratory Corporation of America Holdings: Revenue (by Region), 2019Figure 15.48: Laboratory Corporation of America Holdings: SWOT AnalysisFigure 15.49: CENTOGENE N.V.: Overall Product PortfolioFigure 15.50: CENTOGENE N.V.: Overall Financials, 2017-2019Figure 15.51: CENTOGENE N.V.: Revenue (by Segment), 2017-2019Figure 15.52: CENTOGENE N.V.: Sales (by Region), 2017-2019Figure 15.53: CENTOGENE N.V.: R&D Expenditure, 2017-2019Figure 15.54: CENTOGENE N.V.: SWOT AnalysisFigure 15.55: Thermo Fisher Scientific, Inc.: Product PortfolioFigure 15.56: Thermo Fisher Scientific Inc.: Overall Financials, 2018-2020Figure 15.57: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2018-2020Figure 15.58: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020Figure 15.59: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020Figure 15.60: Thermo Fisher Scientific Inc.: SWOT AnalysisFigure 15.61: Myriad Genetics, Inc.: Product PortfolioFigure 15.62: Myriad Genetics, Inc.: Overall Financials, 2018-2020Figure 15.63: Myriad Genetics, Inc.: Revenue (by Business Segment), 2018-2020Figure 15.64: Myriad Genetics, Inc.: R&D Expenditure, 2018-2020Figure 15.65: Myriad Genetics, Inc.: SWOT AnalysisFigure 15.66: Konica Minolta, Inc: Product portfolioFigure 15.67: Konica Minolta, Inc.: Overall Financials, 2017-2019Figure 15.68: Konica Minolta, Inc.: Revenue (by Business Segment), 2017-2019Figure 15.69: Konica Minolta, Inc.: Regional revenue, 2017-2019Figure 15.70: Konica Minolta, Inc.: R&D Expenditure, 2017-2019Figure 15.71: Konica Minolta, Inc: SWOT AnalysisFigure 15.72: Fulgent Genetics: Product PortfolioFigure 15.73: Fulgent Genetics: Overall Financials, 2018-2020Figure 15.74: Fulgent Genetics: Revenue (by Business Segment), 2018-2020Figure 15.75: Fulgent Genetics: Revenue (by Region), 2018-2020Figure 15.76: Fulgent Genetics: R&D Expenditure, 2018-2020Figure 15.77: Fulgent Genetics: SWOT AnalysisFigure 15.78: PreventionGenetics: Product portfolioFigure 15.79: PreventionGenetics: SWOT Analysis